# US 2021/0277100 A1 · TGFBeta Antibodies, Methods and Uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277100 A1
- Document ID: US20210277100A1
- Status: Published application
- Kind: A1
- Application number: 17/329,859
- Filed: 2021-05-25
- Published: 2021-09-09
- Earliest claimed: 2016-07-14
- Assignees: Scholar Rock, Inc.
- Applicants: Scholar Rock, Inc.
- Inventors: Gregory J. Carven; Thomas Schurpf; Katherine Turner
- Web page: https://patentgrep.com/patent/US20210277100A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 38/18: Growth factors; Growth regulators
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C12N 9/00: Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth A61K8/66, A61Q11/00; medicinal preparations containing enzymes or proenzymes A61K38/43; enzyme containing detergent compositions C11D; {enzymes with nucleic acid structure, e.g. ribozymes, C12N15/113}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt C12C1/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

ProTGFβ1-GARP complex-selective antibodies, polynucleotides capable of encoding the proTGFβ1-GARP complex-selective antibodies or antigen-binding fragments, cells expressing proTGFβ1-GARP complex-selective antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled proTGFβ1-GARP complex-selective antibodies or antigen-binding fragments may be used to enhance an immune response in a subject, for example, against a cancer.

## Claims

### Claim 1

An isolated antibody, or an antigen-binding fragment thereof, wherein the antibody or antigen binding fragment specifically binds to human proTGFβ1 in a complex with human glycoprotein A repetitions predominant (proTGFβ1-GARP complex) while said complex is in solution and the antibody or antigen binding fragment thereof has no detectable binding according to the biolayer interferometry assay using the experimental design described in Example 4 to any of the following agents:
a TGFβ1 growth factor domain,
a TGFβ2 growth factor domain,
a TGFβ3 growth factor domain,
proTGFβ1 covalently associated with LTBP1,
proTGFβ1 covalently associated with LTBP3,
proTGFβ1 covalently associated with LRRC33, and
proTGFβ1 that is unassociated with human GARP,
a. as measured by OctetRed 384 under the conditions shown in Examples 4 and 6 and further wherein the antibody or antigen-binding fragment thereof has an inhibitory concentration (IC50) of less than or equal to 10 nM for inhibition of TGFβ1 growth factor release from a cell-associated proTGFβ1-GARP complex under the conditions shown in Example wherein the antibody or antigen binding fragment comprises:
b. a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 4, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 5, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 6, a light chain CDR1 having the amino acid sequence of SEQ ID NO: 7, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 8, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 9; or
c. a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 10, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 11, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 12, a light chain CDR1 having the amino acid sequence of SEQ ID NO: 13, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 14, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 15.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment of claim 1 wherein the antibody or antigen-binding fragment inhibits Treg function in vitro.

### Claim 3 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein the antibody or antigen binding fragment thereof inhibits the activation of TGFβ1.

### Claim 4 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein the antibody or antigen binding fragment thereof binds to an epitope of human proTGFβ1 modified as a result of complex formation with human GARP.

### Claim 5 (depends on 1)

The antibody or antigen-binding fragment of claim 1, wherein the antibody or antigen binding fragment thereof binds to a polypeptide having the amino acid sequence of SEQ ID NO: 2 in the presence of a polypeptide having the amino acid sequence of SEQ ID NO: 1.

### Claim 6 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antigen-binding fragment thereof specifically binds to human proTGFβ1 with a binding affinity of at least 880 pM as measured by biolayer interferometry assay using the experimental design described in Example 4.

### Claim 7 (depends on 5)

The antibody or antigen-binding fragment of claim 5, wherein the antibody or antigen-binding fragment thereof binds to human proTGFβ1 with a dissociation constant (Kd) of less than or equal to 1 nM for human proTGFβ1 in a complex with human glycoprotein A repetitions predominant (proTGFβ1-GARP complex) under the conditions shown in Example 7 and wherein said proTGFβ1-GARP complex is in solution.

### Claim 8

An isolated antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable region selected from the group consisting of the amino acid sequences of SEQ ID NOs: 16 and 18 and a light chain variable region selected from the group consisting of the amino acid sequences of SEQ ID NOs: 17 and 19.

### Claim 9 (depends on 9)

The antibody or antigen-binding fragment of claim 9, wherein
a. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 16 paired with a light chain variable region comprising the amino acid sequence of SEQ ID NO: 17; or
b. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 18 paired with a light chain variable region comprising the amino acid sequence of SEQ ID NO: 19.

### Claim 10 (depends on 11)

The antigen-binding fragment of claim 11 wherein the antigen binding fragment is a Fab fragment, a Fab2 fragment, or a single chain antibody.

### Claim 11 (depends on 11)

The antibody or antigen-binding fragment of claim 11 wherein the antibody or antigen-binding fragment is recombinant.

### Claim 12 (depends on 13)

The antibody or antigen-binding fragment of claim 13 wherein the antibody or antigen-binding fragment thereof are of IgG1, IgG2, IgG3, or IgG4 isotype.

### Claim 13 (depends on 14)

The antibody or antigen-binding fragment of claim 14, wherein the antibody is an IgG4 isotype.

### Claim 14

An isolated antibody, or an antigen-binding fragment thereof, comprising:
a. a heavy chain CDR1 having at least 80% identity to the amino acid sequence of SEQ ID NO: 4, a heavy chain CDR2 having at least 80% identity to the amino acid sequence of SEQ ID NO: 5, and a heavy chain CDR3 having at least 80% identity to the amino acid sequence of SEQ ID NO: 6, a light chain CDR1 having at least 80% identity to the amino acid sequence of SEQ ID NO: 7, a light chain CDR2 having at least 80% identity to the amino acid sequence of SEQ ID NO: 8, and a light chain CDR3 having at least 80% identity to the amino acid sequence of SEQ ID NO: 9; or
b. a heavy chain CDR1 having at least 80% identity to the amino acid sequence of SEQ ID NO: 10, a heavy chain CDR2 having at least 80% identity to the amino acid sequence of SEQ ID NO: 11, and a heavy chain CDR3 having at least 80% identity to the amino acid sequence of SEQ ID NO: 12, a light chain CDR1 having at least 80% identity to the amino acid sequence of SEQ ID NO: 13, a light chain CDR2 having at least 80% identity to the amino acid sequence of SEQ ID NO: 14, and a light chain CDR3 having at least 80% identity to the amino acid sequence of SEQ ID NO: 15.

### Claim 15

An isolated antibody, or an antigen-binding fragment thereof, comprising:
a. a heavy chain variable region having at least 80% identity to the amino acid sequence of SEQ ID NO: 16 paired with a light chain variable region having at least 80% identity to the amino acid sequence of SEQ ID NO: 17; or
b. a heavy chain variable region having at least 80% identity to the amino acid sequence of SEQ ID NO: 18 paired with a light chain variable region having at least 80% identity to the amino acid sequence of SEQ ID NO: 19.

### Claim 16 (depends on 11)

A polynucleotide encoding the antibody or antigen binding fragment of claim 11.

### Claim 17 (depends on 18)

A vector comprising the polynucleotide of claim 18.

### Claim 18 (depends on 19)

A host cell comprising the vector of claim 19.

### Claim 19 (depends on 20)

A process for the production of an antibody or antigen-binding fragment, comprising:
culturing the host cell as defined in claim 20 under the conditions allowing the expression of the antibody or antigen-binding fragment, and recovering the antibody or antigen-binding molecule from the culture.

### Claim 20 (depends on 11)

A pharmaceutical composition comprising the antibody, or antigen binding fragment thereof, of claim 11 and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 11)

A kit comprising the antibody, or antigen binding fragment thereof, of claim 11 and packaging for the same.
